title: A Phase 1 study of the novel gamma-secretase inhibitor PF-03084014 in patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma.
authors.affiliation: Department of Experimental, Diagnostic, and Specialty Medicine, University of Bologna, Bologna, Italy.
authors.forename: C
authors.initials: C
authors.lastname: Papayannidis
authors.affiliation: Adult Leukemia Institute, Dana-Farber Cancer Institute, Boston, MA, USA.
authors.forename: D J
authors.initials: DJ
authors.lastname: DeAngelo
authors.affiliation: Department of Medicine, Hematology/Oncology Section, University of Chicago, Chicago, IL, USA.
authors.forename: W
authors.initials: W
authors.lastname: Stock
authors.affiliation: Pfizer Oncology, Groton, CT, USA.
authors.forename: B
authors.initials: B
authors.lastname: Huang
authors.affiliation: Pfizer Oncology, San Diego, CA, USA.
authors.forename: M N
authors.initials: MN
authors.lastname: Shaik
authors.affiliation: Pfizer Oncology, Milan, Italy.
authors.forename: R
authors.initials: R
authors.lastname: Cesari
authors.affiliation: Pfizer Oncology, San Diego, CA, USA.
authors.forename: X
authors.initials: X
authors.lastname: Zheng
authors.affiliation: Pfizer Oncology, San Diego, CA, USA.
authors.forename: J M
authors.initials: JM
authors.lastname: Reynolds
authors.affiliation: Pfizer Oncology, San Diego, CA, USA.
authors.forename: P A
authors.initials: PA
authors.lastname: English
authors.affiliation: Pfizer Oncology, San Diego, CA, USA.
authors.forename: M
authors.initials: M
authors.lastname: Ozeck
authors.affiliation: Department of Pathology, Dana Farber Cancer Institute, Boston, MA, USA.
authors.forename: J C
authors.initials: JC
authors.lastname: Aster
authors.affiliation: Department of Pathology, Dana Farber Cancer Institute, Boston, MA, USA.
authors.forename: F
authors.initials: F
authors.lastname: Kuo
authors.affiliation: Pfizer Oncology, San Diego, CA, USA.
authors.forename: D
authors.initials: D
authors.lastname: Huang
authors.affiliation: Pfizer Oncology, San Diego, CA, USA.
authors.forename: P D
authors.initials: PD
authors.lastname: Lira
authors.affiliation: Pfizer Oncology, San Diego, CA, USA.
authors.forename: K R
authors.initials: KR
authors.lastname: McLachlan
authors.affiliation: Pfizer Oncology, San Diego, CA, USA.
authors.forename: K A
authors.initials: KA
authors.lastname: Kern
authors.affiliation: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: G
authors.initials: G
authors.lastname: Garcia-Manero
authors.affiliation: Department of Experimental, Diagnostic, and Specialty Medicine, University of Bologna, Bologna, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Martinelli
mesh_terms: D000293:Adolescent; D000328:Adult; D000970:Antineoplastic Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D005260:Female; D059014:High-Throughput Nucleotide Sequencing; D006801:Humans; D008297:Male; D054218:Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000235:genetics; D051881:Receptor, Notch1 / Q000235:genetics; D013764:Tetrahydronaphthalenes / Q000627:therapeutic use*; D014633:Valine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; C497761:NOTCH1 protein, human; D051881:Receptor, Notch1; D013764:Tetrahydronaphthalenes; D014633:Valine; C550722:nirogacestat